Research Publication Highlights

Clinical Outcomes Following Stereotactic Radiosurgery for Brain Metastases from Sarcoma Primaries

Cancer, Jul 2025;131(13):e35931

Leiomyosarcoma Therapeutic Approaches and Future Directions

Hematology/Oncology Clinics of North America

Emerging Role of Blood-based Biomarkers in Sarcomas

Hematology/Oncology Clinics of North America

Phase II Multi-Center Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma

Siontis BL, Rice JD, Schuetze SM et al.

Clin Cancer Res. May 2025

Histology-Driven Tailoring of Surgical Approaches in Retroperitoneal Soft Tissue Sarcoma

Musa J, Willis F, Rompen IF et al.

BJS Open. 2025;9(3):zraf050

Myxoid Leiomyosarcoma of the Uterus – A Case Report

Oncology Letters

Comprehensive Mutational Profiling Identifies New Driver Events in Cutaneous Leiomyosarcoma

British Journal of Dermatology

Exploration of the Mutational Landscape of Cutaneous Leiomyoma Confirms FH as a Driver Gene and Identifies Targeting Purine Metabolism as a Therapeutic Strategy

British Journal of Dermatology

Doxorubicin–Trabectedin in Leiomyosarcoma

Dr. Patricia Pautier

N Engl J Med 2024;391:2057-2058

Randomized Phase IIb/III Study: Lurbinectedin + Doxorubicin vs. Doxorubicin Alone as First-Line Treatment in Metastatic LMS

J Clin Oncology (ASCO 2024)

ARGSARC: ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated LMS — Phase 3 RCT

MSKCC

Leiomyosarcoma of the Abdomen and Retroperitoneum: A Systematic Review

Frontiers in Surgery

Phase Ib: Doxorubicin, Dacarbazine, and Nivolumab as Upfront Treatment in Advanced LMS (GEIS)

PI: Dr. Javier Martín-Broto (NLMSF International Research Roundtable)

JCO doi:10.1200/JCO.24.00358

Immunotherapy in Sarcoma: Current Data and Promising Strategies

Wood GE, Meyer C, Petitprez F, D'Angelo SP

ASCO Educational Book

Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma

Josephine K. Dermawan

Clin Cancer Res (2024) 30(10): 2260–2271

Leiomyosarcoma – Continuing Education Activity

NIH National Library of Medicine

New Therapeutics for Soft Tissue Sarcomas: Overview of Current Immunotherapy and Future Directions

Gyuhee Seong, Sandra D'Angelo

Frontiers in Oncology

High Grade Sarcomas with Myogenic Differentiation Harboring Hotspot PDGFRB Mutations

Cancer Genetics

The Biology and Treatment of Leiomyosarcoma

Kerrison WGJ, Thway K, Jones RL, Huang PH

Targeting the Molecular and Immunologic Features of Leiomyosarcoma

Cancers (MDPI)

Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas

Clin Cancer Res

Not All Leiomyosarcomas Are the Same: How to Best Classify LMS

Therapeutic Advances in Leiomyosarcoma

Lacuna K, Bose S, Ingham M, Schwartz G

Frontiers in Oncology

Clinical Characteristics of Sarcoma Cases With Long-Term Disease Control With Trabectedin

Emerging Trends in Immunotherapy for Adult Sarcomas

Husain M, Chen L, Liebner D et al.

The Oncologist

Use of Trabectedin in the Treatment of LMS — Video Presentation (Dr. Jonathan Trent)

Molecular Subtypes of Leiomyosarcoma: Moving Toward a Consensus

Landmark Series: Review of Landmark Studies in Treatment of Primary Localized Retroperitoneal Sarcoma

Phase II Clinical Trial of Eribulin–Gemcitabine in Advanced Liposarcoma or Leiomyosarcoma

Clin Cancer Res

Phase Ib/II Study of Lenvatinib + Eribulin in Advanced LPS and LMS (LEADER): Efficacy Updates

J Clin Oncology

Retroperitoneal Leiomyosarcoma Nomogram Model

Scientific Reports (Nature)

Sounding the Alarm on Leiomyosarcoma Recurrence: Role of Circulating Tumor DNA

Kasper B, Wilky BA — NLMSF-SPAEN IRR

Clin Cancer Res

Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors (Dr. Matthew Hemming)

Clin Cancer Res

Preoperative Differentiation of Uterine Leiomyomas and Leiomyosarcomas: Current Possibilities and Future Directions

What Clinical Trials Are Needed for Treatment of Leiomyosarcoma?

Proteomic and Metabolomic Profiling in Soft Tissue Sarcomas

Current Treatment Options in Oncology

Large Scale Multiomic Analysis Suggests Mechanisms of Resistance to Immunotherapy in LMS

ASCO Annual Meeting 2021

Multiomic Analysis to Reveal Distinct Molecular Profiles of Uterine and Nonuterine Leiomyosarcoma

ASCO Annual Meeting 2021

Prognostic Relevance of the Hexosamine Biosynthesis Pathway in Leiomyosarcoma

Surgical Resection of LMS of the Inferior Vena Cava: A Case Series and Literature Review

Relationships Between Highly Recurrent Tumor Suppressor Alterations in 489 Leiomyosarcomas

LMS-02 Study: Doxorubicin in Combination with Trabectedin as First-Line Treatment for Advanced LMS — Final Results (ASCO 2020)

Patricia Pautier, MD — Institut Gustave Roussy

ASCO Annual Meeting 2020

Preliminary Results Presented at ASCO: Promising Clinical Efficacy with Unesbulin in LMS

Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma

Amin-Mansour A, George S, Sioletic S et al.

Clin Cancer Res

BRCA 1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma

Overall Survival from Phase 3 RCT: Trabectedin or Dacarbazine in Advanced LPS or LMS

Cancer

CT Imaging Improves Histopathological Grading of Retroperitoneal Leiomyosarcomas

Effect of Adjuvant Therapy on the Risk of Recurrence in Early-Stage Leiomyosarcoma: A Meta-Analysis

Identifying and Targeting Cancer Stem Cells in Leiomyosarcoma: Prognostic Impact and Role to Overcome Secondary Resistance

J Hematology & Oncology

Discovery and Characterization of Novel, Recurrent, Targetable ALK Fusions in Leiomyosarcoma (Dr. Lara Davis, OHSU)

Soft Tissue and Uterine Leiomyosarcoma

George S, Serrano C, Hensley ML, Ray-Coquard I

J Clin Oncology

Pembrolizumab in Advanced Soft-Tissue Sarcoma and Bone Sarcoma (SARC028): Multicentre Phase 2 Trial

The Lancet Oncology

Gemcitabine and Docetaxel vs. Doxorubicin as First-Line Treatment in Advanced Unresectable STS

The Lancet Oncology

Nivolumab With Ipilimumab for Pretreated Metastatic Sarcoma

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: Phase 2 Trial

Expression and Role of TYRO3 and AXL as Potential Therapeutic Targets in Leiomyosarcoma

British Journal of Cancer

A Vimentin Binding Small Molecule Leads to Mitotic Disruption in Mesenchymal Cancers

PNAS

Machine Learning Analysis of Gene Expression Data Reveals Novel Diagnostic and Prognostic Biomarkers for Soft Tissue Sarcomas

Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib

Sarcoma

External Beam Radiation Therapy for Resectable Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis

Mocetinostat Combined with Gemcitabine for the Treatment of Leiomyosarcoma: Preclinical Correlates